X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PFIZER - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PFIZER TORRENT PHARMA/
PFIZER
 
P/E (TTM) x 29.0 31.4 92.3% View Chart
P/BV x 5.5 5.0 110.4% View Chart
Dividend Yield % 1.0 0.6 152.3%  

Financials

 TORRENT PHARMA   PFIZER
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
PFIZER
Mar-16
TORRENT PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,7682,724 64.9%   
Low Rs1,1861,611 73.6%   
Sales per share (Unadj.) Rs346.1440.9 78.5%  
Earnings per share (Unadj.) Rs55.248.7 113.3%  
Cash flow per share (Unadj.) Rs73.375.8 96.7%  
Dividends per share (Unadj.) Rs14.0015.00 93.3%  
Dividend yield (eoy) %0.90.7 137.0%  
Book value per share (Unadj.) Rs257.1462.9 55.5%  
Shares outstanding (eoy) m169.2245.75 369.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.9 86.8%   
Avg P/E ratio x26.844.5 60.1%  
P/CF ratio (eoy) x20.128.6 70.4%  
Price / Book Value ratio x5.74.7 122.7%  
Dividend payout %25.430.8 82.4%   
Avg Mkt Cap Rs m249,88799,163 252.0%   
No. of employees `00011.82.9 407.8%   
Total wages/salary Rs m9,9342,758 360.3%   
Avg. sales/employee Rs Th4,971.56,981.7 71.2%   
Avg. wages/employee Rs Th843.2954.5 88.3%   
Avg. net profit/employee Rs Th792.4771.1 102.8%   
INCOME DATA
Net Sales Rs m58,56920,170 290.4%  
Other income Rs m2,233857 260.4%   
Total revenues Rs m60,80221,028 289.2%   
Gross profit Rs m13,7734,310 319.6%  
Depreciation Rs m3,0691,239 247.8%   
Interest Rs m2,0565 39,530.8%   
Profit before tax Rs m10,8813,923 277.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m1,5451,794 86.1%   
Profit after tax Rs m9,3362,228 419.1%  
Gross profit margin %23.521.4 110.1%  
Effective tax rate %14.245.7 31.0%   
Net profit margin %15.911.0 144.3%  
BALANCE SHEET DATA
Current assets Rs m53,84116,299 330.3%   
Current liabilities Rs m31,6127,594 416.3%   
Net working cap to sales %38.043.2 87.9%  
Current ratio x1.72.1 79.4%  
Inventory Days Days9765 148.9%  
Debtors Days Days8426 325.3%  
Net fixed assets Rs m42,0798,622 488.1%   
Share capital Rs m846458 185.0%   
"Free" reserves Rs m42,65520,722 205.8%   
Net worth Rs m43,50121,180 205.4%   
Long term debt Rs m22,40825 89,633.2%   
Total assets Rs m101,25029,137 347.5%  
Interest coverage x6.3755.5 0.8%   
Debt to equity ratio x0.50 43,640.6%  
Sales to assets ratio x0.60.7 83.6%   
Return on assets %11.37.7 146.8%  
Return on equity %21.510.5 204.0%  
Return on capital %19.619.0 103.3%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m20,06652 38,850.7%   
Fx outflow Rs m5,304140 3,789.2%   
Net fx Rs m14,762-88 -16,712.7%   
CASH FLOW
From Operations Rs m10,1273,436 294.7%  
From Investments Rs m-7,869-6,991 112.6%  
From Financial Activity Rs m-1,918-619 310.0%  
Net Cashflow Rs m212-4,174 -5.1%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 7.0 7.5 93.6%  
FIIs % 12.6 4.9 257.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 23.7 37.1%  
Shareholders   26,511 85,207 31.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS